Cargando…
Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357
Autores principales: | Liu, Liang, Gao, Quanli, Jiang, Jingting, Zhang, Junping, Song, Xin, Cui, Jiuwei, Ye, Yunbin, Wang, Zhiyu, Zhang, Xinwei, Ren, Xiubao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572396/ https://www.ncbi.nlm.nih.gov/pubmed/33077722 http://dx.doi.org/10.1038/s41392-020-00337-x |
Ejemplares similares
-
Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells
por: Hui, Zhenzhen, et al.
Publicado: (2015) -
Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature review
por: Zhang, Yong, et al.
Publicado: (2017) -
High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study
por: Zhao, Lingdi, et al.
Publicado: (2022) -
Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
por: Han, Ying, et al.
Publicado: (2020) -
Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer
por: Li, Man, et al.
Publicado: (2018)